Oncology Drug Development Not Advanced By Non-Inferiority Trials – Pazdur
Superiority trials should be favored over non-inferiority studies for oncology drug development, FDA Oncology Drug Products Division Director Richard Pazdur, MD, suggested
Superiority trials should be favored over non-inferiority studies for oncology drug development, FDA Oncology Drug Products Division Director Richard Pazdur, MD, suggested